Navigation Links
Most Off-Label Cancer Drug Use for Palliative Care
Date:10/27/2008

International review finds it's an accepted treatment in adults as well as children

MONDAY, Oct. 27 (HealthDay News) -- Between 1990 and 2002, off-label use of anticancer drugs in adults and children ranged between 6.7 percent and 33.2 percent, and most of that off-label use was for palliative care, say researchers who reviewed published studies from a number of countries.

In off-label use, a drug is used to treat conditions that aren't described on the official labeling created when a drug is approved by a regulatory agency such as the U.S. Food and Drug Administration.

Although off-label use of cancer drugs has been reported for most types of cancer, it's most common among patients with metastatic or advanced cancer who are receiving palliative care, noted study author Dr. Dominique Leveque, of the Hopital Hautepierre in Strasbourg, France.

While these patients aren't generally expected to experience clinical benefit, there are circumstances in which off-label anticancer drugs are accepted as the standard of care, such as the use of high-dose carboplatin in some childhood cancers.

But safety is a concern in off-label use, because there's likely little information about tolerance or side effects associated with this kind of use, Leveque said.

He concluded that more research into the extent of off-label use of anticancer drugs is needed and that accurate and unbiased data is urgently required to help doctors make treatment decisions.

The review was published in the November issue of The Lancet Oncology.

More information

The American Cancer Society has more about off-label drug use.



-- Robert Preidt



SOURCE: The Lancet Oncology, news release, Oct. 27, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Biopharmaceutical Company, Cephalon, To Pay $425 Million & Enter Plea to Resolve Allegations of Off-Label Marketing
2. Abortion drugs off-label use may have led to deaths
3. Off-Label Drug Use Needs Strong Oversight
4. Otsuka to Pay More Than $4 Million to Resolve Off-Label Marketing Allegations Involving Abilify
5. Largest ever analysis of DES data demonstrates safety, efficacy in on-and-off-label use
6. Statement from Eli Lilly and Company: Response to Todays New York Times Article, Lilly E-Mail Discussed Off-Label Drug Use
7. Off-Label Avastin Use for Wet Macular Degeneration
8. Study looks at off-label use of biliary stents
9. Get Screened Video Contest Throws a Spotlight on the Importance of Colorectal-Cancer Screening
10. MicroRNAs make for safer cancer treatments
11. Karmanos Cancer Center Most Preferred Hospital for Cancer Care in Southeast Michigan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Las Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... of 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum ... CBD dose required and providing a CBD form that can be easily incorporated into ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term ... long-term care insurance companies have a waiver for care if the client has a ... when the family pays for care, is often waived, so the benefits from their ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Yisrayl Hawkins, ... week that explains one of the most popular and least understood books in the ... cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed it ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2, 2017  Eli Lilly and Company (NYSE: ... the third quarter of 2017 on Tuesday, October 24, ... that day with the investment community and media to ... conference call will begin at 9 a.m. Eastern time. ... live webcast of the conference call through a link ...
(Date:9/28/2017)... -- Cohen Veterans Bioscience and Early Signal Foundation announce ... home sensors for real-time monitoring of patients with trauma-related ... organization focused on disruptive health solutions for rare disorders ... to record and integrate behavioral, cognitive, physiological and contextual ... ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
Breaking Medicine Technology: